Methylated RASSF1a Is the first specific DNA marker for minimal residual disease testing in neuroblastoma

Clinical Cancer Research

Volumn 18, Issue 3, 2012, Pages 808-814

  Stutterheim, Janine ^a,b,c   Ichou, Fatima Ait ^c   Den Ouden, Emmy ^b   Versteeg, Rogier ^b   Caron, Huib N ^a   Tytgat, Godelieve A M ^a   Van Der Schoot, C Ellen ^b,c  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c SANQUIN RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA MARKER; DNA METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NEUROBLASTOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

DNA METHYLATION; GENETIC MARKERS; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEUROBLASTOMA; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84856557430     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0849     Document Type: Article

References (29)

1. Burchill SA, Lewis IJ, Abrams KR, Riley R, Imeson J, Pearson AD, et al. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol 2001;19:1795-801. (Pubitemid 32230882)
2. Cheung IY, Lo Piccolo MS, Kushner BH, Kramer K, Cheung NK. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol 2003;21:1087-93. (Pubitemid 46594138)
3. Trager C, Kogner P, Lindskog M, Ponthan F, Kullman A, Kagedal B. Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow. Clin Chem 2003;49:104-12. (Pubitemid 36078559)
4. Cheung NK, Von Hoff DD, Strandjord SE, Coccia PF. Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies. J Clin Oncol 1986;4:363-9. (Pubitemid 16133089)
5. Beiske K, Burchill SA, Cheung IY, Hiyama E, Seeger RC, Cohn SL, et al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer 2009;100:1627-37.
6. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L, et al. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol 2008;26:5443-9.
7. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Yalcin B, Dee R, van Noesel MM, et al. Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clin Chem 2009;55:1316-26.
8. Banelli B, Gelvi I, Di VA, Scaruffi P, Casciano I, Allemanni G, et al. Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors. Oncogene 2005;24:5619-28. (Pubitemid 43119355)
9. Hoebeeck J, Michels E, Pattyn F, Combaret V, Vermeulen J, Yigit N, et al. Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer Lett 2009;273:336-46.
10. Lazcoz P, Munoz J, Nistal M, Pestana A, Encio I, Castresana JS. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma. BMC Cancer 2006;6:254.
11. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000;25:315-9. (Pubitemid 30437320)
12. Misawa A, Tanaka S, Yagyu S, Tsuchiya K, Iehara T, Sugimoto T, et al. RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker. Br J Cancer 2009;100:399-404.
13. Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen HR, et al. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res 2004;10:8493-500. (Pubitemid 40053415)
14. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11: 1466-77. (Pubitemid 23228250)
15. de Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, Caron HN. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer 2008;44:551-6.
16. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 2008;9:247-56. (Pubitemid 351722944)
17. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005;6:649-58. (Pubitemid 41222755)
18. Verhagen OJ, Willemse MJ, Breunis WB, Wijkhuijs AJ, Jacobs DC, Joosten SA, et al. Application of germline IGH probes in real-time quantitative PCR for the detection ofminimal residual disease in acute lymphoblastic leukemia. Leukemia 2000;14:1426-35. (Pubitemid 30599324)
19. Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002;160:605-12. (Pubitemid 34160338)
20. van dV V, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer- Grumayer ER, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007;21:604-11.
21. Chan KC, Ding C, Gerovassili A, Yeung SW, Chiu RW, Leung TN, et al. Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem 2006;52:2211-8. (Pubitemid 44924994)
22. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001;61:3105-9. (Pubitemid 32691961)
23. Ejeskar K, Aburatani H, Abrahamsson J, Kogner P, Martinsson T. Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene. Br J Cancer 1998;77:1787-91. (Pubitemid 28254612)
24. Vandesompele J, Speleman F, Van RN, Laureys G, Brinskchmidt C, Christiansen H, et al. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there? Med Pediatr Oncol 2001;36:5-10. (Pubitemid 32052986)
25. Trager C, Vernby A, Kullman A, Ora I, Kogner P, Kagedal B. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not ofGD2synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis. Int J Cancer 2008;123:2849-55.
26. Palakurthy RK, Wajapeyee N, Santra MK, Gazin C, Lin L, Gobeil S, et al. Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction ofDNMT3B expression. Mol Cell 2009;36: 219-30.
27. Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer. Dis Markers 2007;23:73-87. (Pubitemid 46333640)
28. Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994;12: 475-82. (Pubitemid 24079887)
29. Gerhard M, Juhl H, Kalthoff H, Schreiber HW, Wagener C, Neumaier M. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 1994;12:725-9. (Pubitemid 24110911)